Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$9.40 ▼ -7.14
(-43.17%)
MKT CAP: $63.3M • VOL: 242.1K
52W L $9 52W H $38
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$8
MEDIAN
$11
MEAN
$11
HIGH
$13
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PTHS TAPE
PTHS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $11.37 | $10.81 | 2025-02-14 | $8.55 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $11.84 | $11.09 | 2025-02-06 | $8.84 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $10.72 | $10.34 | 2025-01-29 | $9.02 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $9.59 | — | 2025-01-17 | $9.21 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $8.27 | $8.93 | 2025-01-09 | $8.37 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $11.19 | $9.78 | 2024-12-18 | $8.18 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.12 | $9.49 | 2024-12-04 | $8.74 | -4.3% | 48% | C |